Tizona to Present at The Cowen and Company 40th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., February 19, 2020 — Tizona Therapeutics, Inc., a clinical stage, privately held company developing first-in-class cancer immunotherapies, announced today that Scott Clarke, Chief Executive Officer, will present at The Cowen and Company 40th Annual Healthcare Conference on Wednesday, March 4th at 2:00pm ET in Boston, MA.
The corporate presentation will be made available on the “news” section of the Tizona website at www.tizonatx.com.
About Tizona Therapeutics, Inc.
Tizona is a privately held, clinical-stage immunotherapy company that develops first-in-class medicines to deliver transformational benefits for people with cancer. Tizona translates scientific breakthroughs into therapeutics that stimulate the immune system and counter immune suppression. Tizona’s lead program, TTX-030, a first-in-class anti-CD39 antibody, is being developed in collaboration with AbbVie. It is currently being studied in a phase 1/1b clinical trial as a monotherapy and in combination with an approved anti-PD-1 agent and standard chemotherapy in adults with advanced cancer (NCT03884556).
Contact:
Investors:
Shari Annes, Annes Associates
sannes@annesassociates.com
650-888-0902
Media:
Janet Graesser
jgraesser@tizonatx.com
917-685-8799